Oncopeptides

Oncopeptides, a Stockholm-based company founded in 2000, specializes in creating medications for the treatment of cancer. The creators of Oncopeptides include some of Sweden's top oncology, clinical, and medical researchers, many of whom have achieved international recognition in their professions.

Melflufen, the first peptidase-potentiated cytotoxic medication designed for use in the treatment of multiple myeloma, was created by Oncopeptides. Oncopeptides has collaborated with eminent scientists and organizations in Europe and the US, such as the Dana Farber Cancer Institute of Harvard Medical School. Data from two phase I/II studies of its medication, melflufen, were presented by researchers in June 2019 at the European Haematology Association in Amsterdam. In 2017, Oncopeptides were listed on the Nasdaq Stockholm.

For difficult-to-treat hemophilia illnesses, Oncopeptides is creating novel therapeutic candidates. The development is based on their Peptide Drug Conjugate (PDC) and Small Polypeptide-based Killer Engagers (SPiKE) technologies and enables us to grow into new indications and build a strong pipeline.

Founded: 2000

Number of employees: 76 employees

Headquarters: Stockholm, Sweden

Website: https://www.oncopeptides.com/en